Closed rkboyce closed 5 years ago
(section 5.2 or 5.3)In particular, where might MedDRA be utilized, where is CTCAE sufficient for oncology ADRs, and does OBI sufficiently represent more global ADRs?
skipping for now. Maybe in the manuscript
(section 5.2 or 5.3)In particular, where might MedDRA be utilized, where is CTCAE sufficient for oncology ADRs, and does OBI sufficiently represent more global ADRs?